← Back to Screener
The Oncology Institute, Inc. Common Stock (TOI)
Price$3.54
Favorite Metrics
Price vs S&P 500 (26W)-17.59%
Price vs S&P 500 (4W)-10.54%
Market Capitalization$339.02M
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)3.85x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.80%
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-6.29%
Gross Margin (TTM)15.20%
Net Profit Margin (TTM)-12.06%
EPS (TTM)$-0.68
10-Day Avg Trading Volume1.32M
EPS Excl Extra (TTM)$-0.68
Revenue Growth (5Y)21.81%
EPS (Annual)$-0.66
ROI (Annual)-66.86%
Gross Margin (Annual)15.20%
Net Profit Margin (5Y Avg)-11.88%
Cash / Share (Quarterly)$0.34
Revenue Growth QoQ (YoY)41.58%
ROA (Last FY)-36.81%
Revenue Growth TTM (YoY)27.79%
EBITD / Share (TTM)$-0.46
ROE (5Y Avg)-401.71%
Operating Margin (TTM)-7.18%
Cash Flow / Share (Annual)$-0.28
P/B Ratio66.88x
P/B Ratio (Quarterly)20.00x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.76x
Net Interest Coverage (TTM)-4.27x
ROA (TTM)-37.18%
EV / EBITDA (TTM)45.58x
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)1.59x
Quick Ratio (Quarterly)1.31x
3-Month Avg Trading Volume1.89M
52-Week Price Return75.90%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.17
P/S Ratio (Annual)0.67x
Asset Turnover (Annual)3.05x
52-Week High$4.88
Operating Margin (5Y Avg)-19.75%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)21.88%
26-Week Price Return-13.60%
Quick Ratio (Annual)1.31x
13-Week Price Return-10.91%
Total Debt / Equity (Annual)25.95x
Current Ratio (Quarterly)1.59x
Enterprise Value$382.853
Revenue / Share Growth (5Y)16.71%
Asset Turnover (TTM)3.08x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)31.68x
Pretax Margin (Annual)-12.08%
Cash / Share (Annual)$0.34
3-Month Return Std Dev82.21%
Gross Margin (5Y Avg)17.61%
Net Income / Employee (TTM)$-0
ROE (Last FY)-1801.70%
Net Interest Coverage (Annual)-4.27x
EPS Basic Excl Extra (Annual)$-0.66
P/FCF (TTM)156.01x
Receivables Turnover (TTM)9.37x
Total Debt / Equity (Quarterly)14.58x
EPS Incl Extra (TTM)$-0.68
Receivables Turnover (Annual)9.37x
ROI (TTM)-64.06%
P/S Ratio (TTM)0.67x
Pretax Margin (5Y Avg)-11.98%
Revenue / Share (Annual)$5.44
Tangible BV / Share (Annual)$0.53
Price vs S&P 500 (52W)46.07%
Year-to-Date Return-3.65%
5-Day Price Return10.29%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-23.85%
Net Profit Margin (Annual)-12.06%
Month-to-Date Return11.73%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$-0.46
Operating Margin (Annual)-7.18%
LT Debt / Equity (Annual)25.95x
ROI (5Y Avg)-34.14%
LT Debt / Equity (Quarterly)14.58x
EPS Basic Excl Extra (TTM)$-0.68
P/TBV (Quarterly)2.56x
P/B Ratio (Annual)6.51x
Inventory Turnover (TTM)31.68x
Pretax Margin (TTM)-12.08%
Book Value / Share (Annual)$0.05
Price vs S&P 500 (13W)-11.60%
Beta0.19x
P/FCF (Annual)140.09x
Revenue / Share (TTM)$4.95
ROE (TTM)-482.58%
52-Week Low$1.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Physicians' Offices(9)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
TOIThe Oncology Institute, Inc. Common Stock | — | 27.79% | -7.18% | -482.58% | $3.54 |
HIMSHims & Hers Health, Inc. | 43.13x | 59.00% | 4.50% | 22.99% | $26.99 |
TDOCTeladoc Health, Inc. | — | -1.54% | -10.39% | -14.24% | $5.82 |
SBCSBC Medical Group Holdings Incorporated Common Stock | 8.75x | — | 43.91% | 21.08% | $4.42 |
AIRSAirSculpt Technologies, Inc. Common Stock | — | -15.82% | -7.61% | -13.79% | $2.60 |
LFMDLifeMD, Inc. Common Stock | 12.80x | 10.59% | -3.28% | 132.06% | $3.94 |
LFMDPLifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock | 12.80x | 10.59% | -3.28% | 132.06% | $23.93 |
AUNAAuna S.A. | 14.09x | -0.02% | 14.26% | 6.08% | $5.52 |
BMGLBasel Medical Group Ltd Ordinary Shares | — | — | -58.56% | -172.53% | $0.60 |
CCMConcord Medical Services Holding Limited | — | 40.12% | -90.64% | -11.58% | $3.91 |
About
The Oncology Institute Inc operates a diversified oncology platform providing infusion services, specialty pharmacy dispensing, stem cell transplants, clinical trials, and supportive care services. The company generates revenue primarily through its patient services segment, with additional contributions from its proprietary dispensary and clinical trials operations. Its integrated model spans diagnosis, treatment, research, and comprehensive patient support across the oncology care continuum.